JP2018521126A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521126A5 JP2018521126A5 JP2018520045A JP2018520045A JP2018521126A5 JP 2018521126 A5 JP2018521126 A5 JP 2018521126A5 JP 2018520045 A JP2018520045 A JP 2018520045A JP 2018520045 A JP2018520045 A JP 2018520045A JP 2018521126 A5 JP2018521126 A5 JP 2018521126A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- certain embodiments
- gw559090a
- ocular
- ocular administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000699 topical effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 210000002159 anterior chamber Anatomy 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 210000000744 eyelid Anatomy 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 231100000607 toxicokinetics Toxicity 0.000 description 4
- 210000003161 choroid Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000011587 new zealand white rabbit Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)C=C[C@@](C(N[C@@](Cc(cc1)ccc1OC(N(CC1)CCC1C(*)=O)=O)C(O)=O)=O)NC(COc1c(C)cccc1)=O Chemical compound CC(C)C=C[C@@](C(N[C@@](Cc(cc1)ccc1OC(N(CC1)CCC1C(*)=O)=O)C(O)=O)=O)NC(COc1c(C)cccc1)=O 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- -1 mists Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940125702 ophthalmic agent Drugs 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189813P | 2015-07-08 | 2015-07-08 | |
| US62/189,813 | 2015-07-08 | ||
| PCT/IB2016/054073 WO2017006272A1 (en) | 2015-07-08 | 2016-07-07 | Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020068158A Division JP2020121985A (ja) | 2015-07-08 | 2020-04-06 | 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521126A JP2018521126A (ja) | 2018-08-02 |
| JP2018521126A5 true JP2018521126A5 (https=) | 2019-08-15 |
| JP6752276B2 JP6752276B2 (ja) | 2020-09-09 |
Family
ID=56373100
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520045A Expired - Fee Related JP6752276B2 (ja) | 2015-07-08 | 2016-07-07 | 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物 |
| JP2020068158A Pending JP2020121985A (ja) | 2015-07-08 | 2020-04-06 | 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020068158A Pending JP2020121985A (ja) | 2015-07-08 | 2020-04-06 | 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10413535B2 (https=) |
| EP (1) | EP3319639B1 (https=) |
| JP (2) | JP6752276B2 (https=) |
| KR (2) | KR102440162B1 (https=) |
| CN (1) | CN107921136A (https=) |
| AU (1) | AU2016290197B2 (https=) |
| BR (1) | BR112018000112A2 (https=) |
| CA (1) | CA2989522C (https=) |
| CL (1) | CL2018000057A1 (https=) |
| ES (1) | ES2835274T3 (https=) |
| HK (1) | HK1247120A1 (https=) |
| IL (2) | IL256770B (https=) |
| MA (2) | MA42016A1 (https=) |
| MX (1) | MX385229B (https=) |
| MY (1) | MY187552A (https=) |
| PL (1) | PL3319639T3 (https=) |
| RU (1) | RU2018103940A (https=) |
| TN (1) | TN2017000538A1 (https=) |
| UA (1) | UA123728C2 (https=) |
| WO (1) | WO2017006272A1 (https=) |
| ZA (1) | ZA201708601B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165218A1 (en) | 2017-03-09 | 2018-09-13 | Allysta Pharmaceuticals, Inc | Peptides for dry eye disease |
| WO2018212846A1 (en) * | 2017-05-19 | 2018-11-22 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| FI3873884T3 (fi) | 2018-10-30 | 2025-02-24 | Gilead Sciences Inc | 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa |
| JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリンの阻害のための化合物 |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| EP3873605B1 (en) | 2018-10-30 | 2024-10-23 | Gilead Sciences, Inc. | Compounds for inhibition of alpha4beta7 integrin |
| JP2022541851A (ja) * | 2019-07-26 | 2022-09-27 | アレグロ ファーマシューティカルズ エルエルシー | 眼の非滲出型黄斑変性および他の障害を治療するためのペプチド |
| WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| IL302175A (en) * | 2020-10-21 | 2023-06-01 | Azura Ophthalmics Ltd | Compounds and methods for the treatment of ocular disorders |
| KR102391198B1 (ko) * | 2021-08-27 | 2022-04-27 | 한림제약(주) | 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828074D0 (en) * | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0014892D0 (en) * | 2000-06-16 | 2000-08-09 | Glaxo Group Ltd | Novel pharmaceutical formulation |
| DK2444079T3 (en) | 2005-05-17 | 2017-01-30 | Sarcode Bioscience Inc | Compositions and Methods for the Treatment of Eye Diseases |
| JP2009514969A (ja) * | 2005-11-09 | 2009-04-09 | コンビナトアールエックス インコーポレーティッド | 医学的状態を治療するための方法、組成物、およびキット |
| US20130217657A1 (en) * | 2011-12-21 | 2013-08-22 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
-
2016
- 2016-07-07 JP JP2018520045A patent/JP6752276B2/ja not_active Expired - Fee Related
- 2016-07-07 RU RU2018103940A patent/RU2018103940A/ru unknown
- 2016-07-07 BR BR112018000112-0A patent/BR112018000112A2/pt not_active Application Discontinuation
- 2016-07-07 KR KR1020187003454A patent/KR102440162B1/ko active Active
- 2016-07-07 EP EP16736636.8A patent/EP3319639B1/en active Active
- 2016-07-07 UA UAA201800954A patent/UA123728C2/uk unknown
- 2016-07-07 MX MX2017017163A patent/MX385229B/es unknown
- 2016-07-07 CN CN201680040066.0A patent/CN107921136A/zh active Pending
- 2016-07-07 AU AU2016290197A patent/AU2016290197B2/en not_active Ceased
- 2016-07-07 KR KR1020227015200A patent/KR20220062688A/ko not_active Ceased
- 2016-07-07 US US15/742,867 patent/US10413535B2/en not_active Expired - Fee Related
- 2016-07-07 HK HK18106821.2A patent/HK1247120A1/zh unknown
- 2016-07-07 TN TNP/2017/000538A patent/TN2017000538A1/en unknown
- 2016-07-07 CA CA2989522A patent/CA2989522C/en active Active
- 2016-07-07 PL PL16736636T patent/PL3319639T3/pl unknown
- 2016-07-07 ES ES16736636T patent/ES2835274T3/es active Active
- 2016-07-07 MY MYPI2017001928A patent/MY187552A/en unknown
- 2016-07-07 WO PCT/IB2016/054073 patent/WO2017006272A1/en not_active Ceased
- 2016-07-07 MA MA42016A patent/MA42016A1/fr unknown
-
2017
- 2017-12-18 ZA ZA2017/08601A patent/ZA201708601B/en unknown
-
2018
- 2018-01-07 IL IL256770A patent/IL256770B/en active IP Right Grant
- 2018-01-08 CL CL2018000057A patent/CL2018000057A1/es unknown
- 2018-02-08 MA MA44935A patent/MA44935A1/fr unknown
-
2019
- 2019-09-12 US US16/569,465 patent/US10751334B2/en not_active Expired - Fee Related
-
2020
- 2020-04-06 JP JP2020068158A patent/JP2020121985A/ja active Pending
- 2020-07-13 US US16/927,825 patent/US20200405703A1/en not_active Abandoned
-
2021
- 2021-02-11 IL IL280827A patent/IL280827A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521126A5 (https=) | ||
| US8791158B2 (en) | Methods of treating meibomian gland dysfunction | |
| JP6209777B2 (ja) | 眼の疾病及び疾患のための組成物及び治療 | |
| AU2011284589B2 (en) | Compounds for the treatment/prevention of ocular inflammatory diseases | |
| US20080312194A1 (en) | Methods and compositions for normalizing meibomian gland secretions | |
| US11759472B2 (en) | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface | |
| CN107982211A (zh) | 眼科治疗 | |
| US10292953B2 (en) | Pharmaceutical composition of ibuprofen and tramadol for ophthalmic use | |
| US12350277B2 (en) | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface | |
| CN115192517A (zh) | 多泡沫体及其眼睑施用 | |
| WO2018033854A1 (en) | Ophthalmic composition and a method for treating ocular hypertension and glaucoma | |
| US20110130451A1 (en) | Method of treating dry eye disorders and uveitis | |
| JPWO2006049250A1 (ja) | 眼内移行性促進水性点眼剤 | |
| JP2017534658A (ja) | プロスタグランジンと一酸化窒素供与体との組み合わせ | |
| CN100522147C (zh) | 5,6,7-三羟基庚酸及其类似物在制备治疗干眼病和眼色素层炎药物中的应用 | |
| US20070112032A1 (en) | Prevention and/or reduction of photoreceptor degeneration with retinoids | |
| TW201705956A (zh) | 唑系抗真菌藥之對眼瞼皮膚的投與 | |
| JP7114668B2 (ja) | エピナスチン又はその塩を含有する花粉破裂抑制剤 | |
| RS64399B1 (sr) | Kompozicije za lečenje oftalmoloških stanja | |
| CN117460501A (zh) | 用于退行性视网膜疾病的trpa1通道拮抗剂化合物 | |
| HK40031764A (en) | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface | |
| HK1241269B (zh) | 前列腺素类和一氧化氮供体的组合产品 |